Blog articles

Gene therapy Casgevy approved for NHS use
The gene therapy Casgevy is now available on the NHS in England for people living with severe forms of beta-thalassaemia and sickle cell disease.

In vivo and ex vivo gene therapies explained
Gene therapies can take place either 'in vivo' or 'ex vivo'; we compare these two approaches and their importance in gene therapy

Hereditary angioedema gene therapy hope
A CRISPR-based genome therapy has shown promising results for patients with a rare genetic swelling disorder

World-first gene therapy trial for Hunter syndrome opens
We explore a new treatment that aims to cross the blood-brain barrier for the first time in Hunter syndrome

Casgevy – how it works
In this week’s article, we revisit Casgevy and explore its utility and application in healthcare

Casgevy – the first CRISPR therapy
The UK has approved a new type of gene therapy for the blood disorders sickle cell disease and beta-thalassaemia, a world-first using CRISPR technology

What are genome editing and gene therapy?
Gene therapy and genome editing technologies are increasingly being reported on in the news and discussed in medical literature, but what are they?

Base editing: What is it and what does it mean for healthcare?
This week, we take an in-depth look at the genome-editing technology that has been making headlines worldwide

'Transformational' cardiomyopathy treatment receives funding
We explore a recently funded heart muscle disease project that will use RNA therapy and gene editing in tandem

Cancer vs the immune system
This week, we explore the ways cancer cells can evade our bodies’ defences and how we can fight back

Trial underway for hATTR therapy
The novel ‘one off’ treatment could change the lives of those living with the condition
Events

LinkAGE Webinar 2: CRISPR
Welcome to the second of our new series of expert webinars. In this second webinar Dr James Patterson will discuss CRISPR.